← Back to screener

Contineum Therapeutics, Inc. CTNM

Rank #1768 · Nasdaq · $0.2B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
42.7
P/E
-5.1
P/B
-3.19
ROE
62.2%
Op. Margin
–%
Debt Ratio
-22%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -5.1x, P/B -3.19x. Ranks in the top 96% of the universe.

Profitability ★★★★★
Excellent

ROE 62.2%. Ranks in the top 6% of the universe.

Safety ★★★★★
Excellent

Debt ratio -22%. Ranks in the top 7% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2024$0.1B$0.0B$0.0B$-0.1B32.2-6
2025–$-0.1B$-0.0B$-0.1B–-22

← See the full screener